S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
U.S. Military Defense Fails Without Vanadium? (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
U.S. Military Defense Fails Without Vanadium? (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

NeuroScientific Biopharmaceuticals Stock Price, News & Analysis (ASX:NSB)

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About NeuroScientific Biopharmaceuticals

NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. It was incorporated in 2002 and is based in Cottesloe, Australia.


NSB Stock News Headlines

May 20, 2022 | finance.yahoo.com
We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely
May 20, 2022 | finance.yahoo.com
We Think NeuroScientific Biopharmaceuticals (ASX:NSB) Needs To Drive Business Growth Carefully
See More Headlines
Receive NSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroScientific Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
ASX:NSB
CUSIP
N/A
CIK
N/A
Web
www.neuroscientific.com
Phone
61 8 6382 1800
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-1,070,000.00
Net Margins
-21.58%
Pretax Margin
N/A
Return on Equity
-20.93%
Return on Assets
-11.24%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.39
Quick Ratio
3.31

Sales & Book Value

Annual Sales
$4.95 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
A$0.03 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
144,600,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.73
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (ASX:NSB) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -